Antimicrobial Optimisation Seminar - Obese Patients
Thankyou for joining us for this CRE RESPOND hybrid seminar. Please find recordings of the presentations below to hear from expert clinicians about optimising antibacterial and antifungal dosing in obese patients.
Program
5.30pm Registrations and light dinner in RBWH Education Centre Foyer
6 pm AEST Welcome and Introduction
Chair and moderator: Dr Mohd Hafiz Abdul-Aziz, Postdoctoral Research Fellow, CRE RESPOND, UQ Centre for Clinical Research, Australia
6.05 pm AEST Antibacterial dosing in obesity - clinical cases
Jack Cross, Pharmacist Advanced, Infectious Diseases - Gold Coast Hospital and Health Service, Australia
6.25 pm AEST Antifungal dosing in obesity
Haifa Lyster, Consultant Pharmacist - Transplantation & VADs, Royal Brompton & Harefield Hospitals, United Kingdom
6.45 pm AEST Questions & Answers
7.10 pm AEST Close
About Antimicrobial Optimisation Webinar series
Infections in the healthcare setting are common and cause too many people to die. Severe infections commonly occur in patients with critical illness, burns, transplant, cystic fibrosis and immunosuppression. Infections in these patients are more difficult to treat, leading to multi-drug resistant (‘superbug’) infections associated with increased mortality and poorer health outcomes.
This Antimicrobial Optimisation workshop will convey the principles of susceptibility testing for antibacterial, antifungal, viral and antimycobacterials. Expert practitioners will describe the principles of drug dosing in different patient populations and clarify the role of therapeutic drug monitoring. The format of the workshop will be four, 20-minute presentations followed by opportunities for questions and answers.
Learning objectives of the Antimicrobial Optimisation Webinar series:
- Principles of susceptibility testing for antibacterial, antifungal, viral and antimycobacterials
- Pharmacokinetic considerations in special patient populations
- Principles of drug dosing in different patient populations
- Role of therapeutic drug monitoring
- Therapeutics for invasive fungal infections and antifungal drugs
Thank you to our program sponsors:
